BCRX Corporate Presentation January 2025.pdf

1、CONFIDENTIAL&PROPRIETARYCorporate PresentationJanuary 2025BioCryst Pharmaceuticals,Inc.Forward-looking statements2BioCrysts presentation contains forward-looking statements,including statements regarding future results,preliminary,unaudited revenue results,and forward-looking financial information a

2、nd company performance,achievements,or future market share or size.These statements are subject to known and unknown risks,uncertainties and other factors which may cause actual results,performance,achievements,or market share or size to be materially different from any preliminary,unaudited revenue

3、 results and future results,performance,achievements,or market share or size expressed or implied in this presentation.These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties.You should not place undue reliance

4、on the forward-looking statements.For additional information,including important risk factors,please refer to BioCrysts documents filed with the SEC and located at growth through the decade with pipeline optionality3 3Financially Independentwith nearwith near-term term path to path to profitabilityp

5、rofitabilitywith nearwith near-term term milestonesmilestonesgrowing to$1B growing to$1B peak annual peak annual salessalesClinical Pipeline Marketed Product2024 highlights and 2025 outlook42024 Results:$437M global ORLADEYO revenue(34%growth)and$450M total revenueOver 1,200 US prescribersCommercial

6、ly available in over 30 countriesORLADEYO pediatric program on track for regulatory submission in 2025BCX17725(Netherton syndrome)and avoralstat(DME)advancing into patients in 2025Achieved goal for full-year 2024 operating profit1 On track for sustainable quarterly positive EPS and cash flow in 2H25